Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials
Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and qu...
Gespeichert in:
Veröffentlicht in: | Journal of the American Society of Nephrology 2004-12, Vol.15 (12), p.3154-3165 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3165 |
---|---|
container_issue | 12 |
container_start_page | 3154 |
container_title | Journal of the American Society of Nephrology |
container_volume | 15 |
creator | STRIPPOLI, Giovanni F. M CRAIG, Jonathan C MANNO, Carlo SCHENA, Francesco P |
description | Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and quality of life, but higher Hb targets may cause access thrombosis and hypertension and are costly. This study aimed to evaluate the benefits and harms of different Hb targets in CKD on the basis of randomized trial evidence. A comprehensive search of the Cochrane Trials Registry, Medline, Embase, and reference lists was performed. Two independent reviewers assessed studies for inclusion criteria and extracted data on all-cause mortality, cardiovascular disease, strokes, hypertension, seizures, hyperkalemia, access thrombosis, and quality of life. Analysis was by a random-effects model, and results are expressed as relative risk (RR) or weighted mean difference with 95% confidence intervals (CI). Nineteen relevant trials were identified. Twelve trials (638 patients) compared use of erythropoietin versus no erythropoietin treatment, and seven trials (2058 patients) compared higher versus lower Hb targets. Compared with Hb values of >130 g/L or more in the CKD population with cardiovascular disease, Hb values of |
doi_str_mv | 10.1097/01.ASN.0000145436.09176.A7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67145859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67145859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-7033ab211c24fb4ea0e52ce6fdcf40b6c0edaf1050aeb66bb9b617e6d0386ebe3</originalsourceid><addsrcrecordid>eNpFkEtPxCAQgInR-P4LhpjoyVZYClhvzcZXYvSgngmPQdG2KHQP668XdZOdy8zhm9eH0DElNSWtPCe07p4ealKCNrxhoiYtlaLu5AbapZyxijWcbJaaNKISQrIdtJfze8H5TMpttEM5ly2n7S4abmGIr300YcSTTq8wZexjwtMbYD3CEDSOHtu3FMdg8UdwIyyxCxl0hkvc4QEmXelR98sc8i-a9OjiEL7BnWEbxynFvgeHn1PQfT5AW74kOFzlffRyffU8v63uH2_u5t19ZcvlUyUJY9rMKLWzxpsGNAE-syC8s74hRlgCTntKONFghDCmNYJKEI6wCwEG2D46_Z_7meLXAvKkhpAt9H15KS6yErKIu-BtAS__QZtizgm8-kxh0GmpKFG_shWhqshWa9nqT7bqZGk-Wm1ZmAHcunVltwAnK0Bnq3tf3NiQ15xgVDSSsx8ggYo_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67145859</pqid></control><display><type>article</type><title>Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>STRIPPOLI, Giovanni F. M ; CRAIG, Jonathan C ; MANNO, Carlo ; SCHENA, Francesco P</creator><creatorcontrib>STRIPPOLI, Giovanni F. M ; CRAIG, Jonathan C ; MANNO, Carlo ; SCHENA, Francesco P</creatorcontrib><description>Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and quality of life, but higher Hb targets may cause access thrombosis and hypertension and are costly. This study aimed to evaluate the benefits and harms of different Hb targets in CKD on the basis of randomized trial evidence. A comprehensive search of the Cochrane Trials Registry, Medline, Embase, and reference lists was performed. Two independent reviewers assessed studies for inclusion criteria and extracted data on all-cause mortality, cardiovascular disease, strokes, hypertension, seizures, hyperkalemia, access thrombosis, and quality of life. Analysis was by a random-effects model, and results are expressed as relative risk (RR) or weighted mean difference with 95% confidence intervals (CI). Nineteen relevant trials were identified. Twelve trials (638 patients) compared use of erythropoietin versus no erythropoietin treatment, and seven trials (2058 patients) compared higher versus lower Hb targets. Compared with Hb values of >130 g/L or more in the CKD population with cardiovascular disease, Hb values of <120 g/L were associated with lower all-cause mortality (RR, 0.84; 95% CI, 0.71 to 1.00). Hb values of 100 g/L or less reduced the risk of hypertension (RR, 0.50; 95% CI, 0.33 to 0.76) but increased the risk of seizures (RR, 5.25; 95% CI, 1.13 to 24.34). From the available trial evidence, in CKD patients with cardiovascular disease, the benefits associated with higher Hb targets (reduced seizures) are outweighed by the harms (increased risk of hypertension and death). There is insufficient data to guide decisions in patients without cardiovascular disease or in the predialysis population.</description><identifier>ISSN: 1046-6673</identifier><identifier>EISSN: 1533-3450</identifier><identifier>DOI: 10.1097/01.ASN.0000145436.09176.A7</identifier><identifier>PMID: 15579519</identifier><identifier>CODEN: JASNEU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Anemia - blood ; Anemia - drug therapy ; Anemia - mortality ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Erythropoietin - analogs & derivatives ; Erythropoietin - therapeutic use ; Hemoglobins ; Humans ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - mortality ; Medical sciences ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Renal failure</subject><ispartof>Journal of the American Society of Nephrology, 2004-12, Vol.15 (12), p.3154-3165</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-7033ab211c24fb4ea0e52ce6fdcf40b6c0edaf1050aeb66bb9b617e6d0386ebe3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16316475$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15579519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STRIPPOLI, Giovanni F. M</creatorcontrib><creatorcontrib>CRAIG, Jonathan C</creatorcontrib><creatorcontrib>MANNO, Carlo</creatorcontrib><creatorcontrib>SCHENA, Francesco P</creatorcontrib><title>Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials</title><title>Journal of the American Society of Nephrology</title><addtitle>J Am Soc Nephrol</addtitle><description>Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and quality of life, but higher Hb targets may cause access thrombosis and hypertension and are costly. This study aimed to evaluate the benefits and harms of different Hb targets in CKD on the basis of randomized trial evidence. A comprehensive search of the Cochrane Trials Registry, Medline, Embase, and reference lists was performed. Two independent reviewers assessed studies for inclusion criteria and extracted data on all-cause mortality, cardiovascular disease, strokes, hypertension, seizures, hyperkalemia, access thrombosis, and quality of life. Analysis was by a random-effects model, and results are expressed as relative risk (RR) or weighted mean difference with 95% confidence intervals (CI). Nineteen relevant trials were identified. Twelve trials (638 patients) compared use of erythropoietin versus no erythropoietin treatment, and seven trials (2058 patients) compared higher versus lower Hb targets. Compared with Hb values of >130 g/L or more in the CKD population with cardiovascular disease, Hb values of <120 g/L were associated with lower all-cause mortality (RR, 0.84; 95% CI, 0.71 to 1.00). Hb values of 100 g/L or less reduced the risk of hypertension (RR, 0.50; 95% CI, 0.33 to 0.76) but increased the risk of seizures (RR, 5.25; 95% CI, 1.13 to 24.34). From the available trial evidence, in CKD patients with cardiovascular disease, the benefits associated with higher Hb targets (reduced seizures) are outweighed by the harms (increased risk of hypertension and death). There is insufficient data to guide decisions in patients without cardiovascular disease or in the predialysis population.</description><subject>Anemia - blood</subject><subject>Anemia - drug therapy</subject><subject>Anemia - mortality</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Erythropoietin - analogs & derivatives</subject><subject>Erythropoietin - therapeutic use</subject><subject>Hemoglobins</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Renal failure</subject><issn>1046-6673</issn><issn>1533-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtPxCAQgInR-P4LhpjoyVZYClhvzcZXYvSgngmPQdG2KHQP668XdZOdy8zhm9eH0DElNSWtPCe07p4ealKCNrxhoiYtlaLu5AbapZyxijWcbJaaNKISQrIdtJfze8H5TMpttEM5ly2n7S4abmGIr300YcSTTq8wZexjwtMbYD3CEDSOHtu3FMdg8UdwIyyxCxl0hkvc4QEmXelR98sc8i-a9OjiEL7BnWEbxynFvgeHn1PQfT5AW74kOFzlffRyffU8v63uH2_u5t19ZcvlUyUJY9rMKLWzxpsGNAE-syC8s74hRlgCTntKONFghDCmNYJKEI6wCwEG2D46_Z_7meLXAvKkhpAt9H15KS6yErKIu-BtAS__QZtizgm8-kxh0GmpKFG_shWhqshWa9nqT7bqZGk-Wm1ZmAHcunVltwAnK0Bnq3tf3NiQ15xgVDSSsx8ggYo_</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>STRIPPOLI, Giovanni F. M</creator><creator>CRAIG, Jonathan C</creator><creator>MANNO, Carlo</creator><creator>SCHENA, Francesco P</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials</title><author>STRIPPOLI, Giovanni F. M ; CRAIG, Jonathan C ; MANNO, Carlo ; SCHENA, Francesco P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-7033ab211c24fb4ea0e52ce6fdcf40b6c0edaf1050aeb66bb9b617e6d0386ebe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anemia - blood</topic><topic>Anemia - drug therapy</topic><topic>Anemia - mortality</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Erythropoietin - analogs & derivatives</topic><topic>Erythropoietin - therapeutic use</topic><topic>Hemoglobins</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Renal failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STRIPPOLI, Giovanni F. M</creatorcontrib><creatorcontrib>CRAIG, Jonathan C</creatorcontrib><creatorcontrib>MANNO, Carlo</creatorcontrib><creatorcontrib>SCHENA, Francesco P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STRIPPOLI, Giovanni F. M</au><au>CRAIG, Jonathan C</au><au>MANNO, Carlo</au><au>SCHENA, Francesco P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials</atitle><jtitle>Journal of the American Society of Nephrology</jtitle><addtitle>J Am Soc Nephrol</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>15</volume><issue>12</issue><spage>3154</spage><epage>3165</epage><pages>3154-3165</pages><issn>1046-6673</issn><eissn>1533-3450</eissn><coden>JASNEU</coden><abstract>Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and quality of life, but higher Hb targets may cause access thrombosis and hypertension and are costly. This study aimed to evaluate the benefits and harms of different Hb targets in CKD on the basis of randomized trial evidence. A comprehensive search of the Cochrane Trials Registry, Medline, Embase, and reference lists was performed. Two independent reviewers assessed studies for inclusion criteria and extracted data on all-cause mortality, cardiovascular disease, strokes, hypertension, seizures, hyperkalemia, access thrombosis, and quality of life. Analysis was by a random-effects model, and results are expressed as relative risk (RR) or weighted mean difference with 95% confidence intervals (CI). Nineteen relevant trials were identified. Twelve trials (638 patients) compared use of erythropoietin versus no erythropoietin treatment, and seven trials (2058 patients) compared higher versus lower Hb targets. Compared with Hb values of >130 g/L or more in the CKD population with cardiovascular disease, Hb values of <120 g/L were associated with lower all-cause mortality (RR, 0.84; 95% CI, 0.71 to 1.00). Hb values of 100 g/L or less reduced the risk of hypertension (RR, 0.50; 95% CI, 0.33 to 0.76) but increased the risk of seizures (RR, 5.25; 95% CI, 1.13 to 24.34). From the available trial evidence, in CKD patients with cardiovascular disease, the benefits associated with higher Hb targets (reduced seizures) are outweighed by the harms (increased risk of hypertension and death). There is insufficient data to guide decisions in patients without cardiovascular disease or in the predialysis population.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15579519</pmid><doi>10.1097/01.ASN.0000145436.09176.A7</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1046-6673 |
ispartof | Journal of the American Society of Nephrology, 2004-12, Vol.15 (12), p.3154-3165 |
issn | 1046-6673 1533-3450 |
language | eng |
recordid | cdi_proquest_miscellaneous_67145859 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Anemia - blood Anemia - drug therapy Anemia - mortality Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Erythropoietin - analogs & derivatives Erythropoietin - therapeutic use Hemoglobins Humans Kidney Failure, Chronic - blood Kidney Failure, Chronic - mortality Medical sciences Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Pharmacology. Drug treatments Randomized Controlled Trials as Topic Renal failure |
title | Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled Trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A45%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemoglobin%20targets%20for%20the%20anemia%20of%20chronic%20kidney%20disease:%20A%20meta-analysis%20of%20randomized,%20controlled%20Trials&rft.jtitle=Journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=STRIPPOLI,%20Giovanni%20F.%20M&rft.date=2004-12-01&rft.volume=15&rft.issue=12&rft.spage=3154&rft.epage=3165&rft.pages=3154-3165&rft.issn=1046-6673&rft.eissn=1533-3450&rft.coden=JASNEU&rft_id=info:doi/10.1097/01.ASN.0000145436.09176.A7&rft_dat=%3Cproquest_cross%3E67145859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67145859&rft_id=info:pmid/15579519&rfr_iscdi=true |